Table 3.
Outcomes after kidney transplantation among maintenance immunosuppression matched pairs; rATG is the reference group
| Clinical Outcomes | Prednisone | No Prednisone | ||
|---|---|---|---|---|
| HR (95% CI) | Paired Cox Model P Value | HR (95% CI) | Paired Cox Model P Value | |
| Alemtuzumab-rATG matches | n=513 Matched Pairs | n=973 Matched Pairs | ||
| Death | 1.37 (0.97 to 1.93) | 0.07 | 1.08 (0.82 to 1.42) | 0.58 |
| Death or allograft failure | 1.35 (1.04 to 1.77) | 0.03 | 1.16 (0.93 to 1.44) | 0.18 |
| Death or sepsis | 1.10 (0.85 to 1.44) | 0.46 | 0.98 (0.79 to 1.22) | 0.87 |
| Death or lymphoma | 1.05 (0.68 to 1.64) | 0.82 | 1.29 (0.90 to 1.86) | 0.17 |
| Death or melanoma | 1.09 (0.68 to 1.74) | 0.72 | 1.26 (0.86 to 1.84) | 0.25 |
| Basiliximab-rATG matches | n=2882 Matched Pairs | n=299 Matched Pairs | ||
| Death | 0.96 (0.85 to 1.09) | 0.56 | 1.15 (0.72 to 1.84) | 0.55 |
| Death or allograft failure | 0.97 (0.87 to 1.08) | 0.62 | 1.21 (0.81 to 1.81) | 0.36 |
| Death or sepsis | 1.03 (0.92 to 1.15) | 0.58 | 0.98 (0.65 to 1.48) | 0.92 |
| Death or lymphoma | 0.97 (0.82 to 1.16) | 0.76 | 1.06 (0.55 to 2.01) | 0.87 |
| Death or melanoma | 0.98 (0.81 to 1.17) | 0.78a | 0.82 (0.44 to 1.53) | 0.53 |
rATG is the reference group. HRs, 95% CIs, and P values computed using a paired Cox proportional hazards model. Outcomes that include those derived from Medicare claims (those using sepsis, lymphoma, melanoma) are censored at 3 years post-transplant.
a
Subsequent analyses suggested the possibility that hazards were nonproportional over time (see Kaplan–Meier figure). The 3-year difference with a bootstrapped 95% CI was −0.1% (−1.9% to 1.8%).